Sulbactam-containing beta-lactamase inhibitor combinations

Clin Microbiol Infect. 2008 Jan:14 Suppl 1:185-8. doi: 10.1111/j.1469-0691.2007.01847.x.

Abstract

Sulbactam irreversibly inhibits the hydrolytic activity of beta-lactamases. This compound is commercially available in combination with either ampicillin or cefoperazone. In each instance, the activity of the partner antibiotic against beta-lactamase-producing bacteria is restored. One of the particular advantages of using sulbactam-containing combinations is that sulbactam itself has inherent activity against some Acinetobacter baumannii. Sulbactam combinations have not demonstrated strong selective pressures for extended-spectrum beta-lactamase-producing Enterobacteriaceae and vancomycin-resistant enterococci. In contrast to clavulanate, sulbactam does not induce class I (Ampc) chromosomal beta-lactamases in Enterobacteriaceae.

Publication types

  • Review

MeSH terms

  • Adult
  • Ampicillin* / administration & dosage
  • Ampicillin* / pharmacokinetics
  • Ampicillin* / therapeutic use
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / pharmacokinetics
  • Anti-Bacterial Agents / therapeutic use
  • Cefoperazone* / administration & dosage
  • Cefoperazone* / pharmacokinetics
  • Cefoperazone* / therapeutic use
  • Drug Combinations
  • Gram-Negative Bacteria / drug effects*
  • Gram-Negative Bacteria / enzymology
  • Gram-Negative Bacterial Infections / drug therapy*
  • Gram-Negative Bacterial Infections / microbiology
  • Humans
  • Microbial Sensitivity Tests
  • Sulbactam* / administration & dosage
  • Sulbactam* / pharmacokinetics
  • Sulbactam* / therapeutic use
  • beta-Lactamase Inhibitors*

Substances

  • Anti-Bacterial Agents
  • Drug Combinations
  • beta-Lactamase Inhibitors
  • Ampicillin
  • Cefoperazone
  • Sulbactam